Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|January 3, 2020
- Pharmaceutical Technology\'s In the Lab eNewsletter-01-08-2020
- Volume 15
- Issue 1
CatSci Announces Appointment of New Board Members
The board consists of industry thought leaders who will work to develop new service offerings for the company.
Advertisement
In an effort to expand its chemistry, manufacturing, and controls capabilities, CatSci, a United Kingdom-based research and development contract research organization (CRO), announced the appointment of members to its new strategic advisory board on Dec. 11, 2019.
The board consists of industry thought leaders who will work to develop new service offerings for the company while improving value for its customer base, increasing its number of small-molecule therapeutics, and creating 500 jobs by 2030, according to a company press release. The board will also introduce two new laboratories to increase capacity at the company.
“We are delighted that CatSci is entering another exciting new phase of its strategic growth plan,” said Dr. Ross Burn, CEO, CatSci, in the press release. “The appointment of this new advisory board is a pivotal step for the company and the new laboratories will enable us to develop more commercially and environmentally sustainable processes for the benefit of patients worldwide. This is an incredibly exciting time to be working at the company, as we continue our journey towards our vision of becoming the preferred partner for process research and development of small-molecule therapeutics.”
The newly appointed board members include:
- Dr. Andy Jones of MedrusPharma Consulting Ltd, board chair
- Dr. Andy Wells of Charnwood Technical Consulting Ltd
- Dr. Mike Rowley of Xelaro Ltd
- Dr. Nigel Richardson, head of Analytical Technology and Automation at GlaxoSmithKline.
Source:
Articles in this issue
over 6 years ago
Ensuring Viral Control in Viral Vector Manufacturingover 6 years ago
Understanding Evolving E&L Regulationsalmost 7 years ago
BHP Opens New Elemental Impurities Testing Facilityalmost 7 years ago
Micromeritics Instrument Launches the SAS II for Particle Sizingalmost 7 years ago
LabTwin Named a Finalist in 2019 Fierce Innovation Awardsalmost 7 years ago
Charles River Partners with Bit Bio for Human Cell Suite ExpansionAdvertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement